Log In
BCIQ
Print this Print this
 

D-Ivacaftor, deuterated ivacaftor (CTP-656) (formerly C-10358)

  Manage Alerts
Collapse Summary General Information
Company Concert Pharmaceuticals Inc.
DescriptionOral deuterium-modified ivacaftor, a potentiator of cystic fibrosis transmembrane conductance regulator (CFTR)
Molecular Target Cystic fibrosis transmembrane conductance regulator (CFTR)
Mechanism of ActionCFTR stabilizer
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationCystic fibrosis (CF)
Indication DetailsTreat cystic fibrosis (CF)
Regulatory Designation U.S. - Orphan Drug (Treat cystic fibrosis (CF))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today